INNOVATION X CHANGE
BY ARENSIA

12 MAY 2026
SHANGHAI
J HOTEL



DR. CLAUDIA HESSELMANN, PhD
Founder & CEO
ARENSIA Exploratory Medicine



DR. HUA YE
Founder & CEO
BIONOVA PHARMACEUTICALS




PROF. DR. WANMING ZHANG
Co-founder, CEO & CMO
QINGDAO WANMING CYBER BIOPHARMACEUTICAL



LILY CHEN
Project Director
HANSOH PHARMA



DR. SHENG FENG, PhD
Chief Scientific Officer
LINKDOC TECHNOLOGY



DR. MICHAEL QIN, PhD
Founder & CEO
ECLINCLOUD



DR. QI FEI, PhD
Executive Director
LEGEND CAPITAL

AMONG THE TOPICS

- **Strategic planning for efficient Proof-of-Concept trials**: regulatory pathways, site selection, and geographic advantages
- **Case studies on accelerating POC trials** with optimized budgets and timeline
- **Updates on the European clinical trial environment**, including CTIS and evolving regulatory frameworks
- **AI-driven and patient-centric trial designs** shaping the future of clinical research

PARTICIPATION BY INVITATION ONLY

CONTACT: LARISA.IVAN@ARENSIA-EM.COM

PROOF-OF-CONCEPT: BOLD MOVES, BIG WINS AND KEY LESSONS

Chinese biotech innovation is moving at extraordinary speed—but global success depends on strategy, not just science. A smart, capital-efficient Proof-of-Concept approach that generates FDA- and EMA-recognized clinical data can unlock global markets and dramatically increase asset value.

At the same time, clinical drug development is entering one of its most challenging eras. Sponsors face fierce competition for patients, geopolitical uncertainty, increasingly complex regulatory frameworks, and rising operational pressure. In this environment, success requires bold planning, agile execution, and unconventional strategies.

Continuing our annual tradition, ARENSIA brings together leading clinical research executives for a one-day, face-to-face forum designed for open and candid discussion of these realities. This event will feature a distinguished panel of experts in early-phase drug development who will share real-world case studies and practical lessons across global regulatory pathways, clinical operations, patient recruitment, and multi-national trial execution.

ARENSIA
EXPLORATORY MEDICINE

AGENDA
AT-A-GLANCE

INNOVATION X CHANGE
BY ARENSIA

REGISTRATION	08:30	12:00
BREAKFAST	09:15	13:00
WELCOME	09:15	13:00
INTRODUCTION	09:30	13:45
HOW INNOVATIVE CHINESE BIOTECHS CAN ACHIEVE GLOBAL PROOF-OF-CONCEPT AND MAXIMIZE THE VALUE OF THEIR SCIENCE?	09:30	13:45
	10:15	14:30
SMART REGULATORY & OPERATIONAL PLANNING		
RIGHT SITES FOR FASTEST PATIENT RECRUITMENT		
CASE STUDY: MINIMAL COST, MAXIMAL SPEED		
		14:30
		14:45
ENTERING THE GLOBAL CLINICAL TRIAL ARENA: STRATEGY BEYOND REGULATION	10:15	14:45
	11:00	15:30
WHERE EARLY-PHASE TRIALS MOVE FASTEST TODAY		
UNDERSTANDING CTIS AND EUROPE'S EVOLVING CLINICAL TRIAL FRAMEWORK		
CASE STUDY: COMMON STRATEGIC MISTAKES FIRST-TIME SPONSORS MAKE		
	11:00	15:30
	11:15	16:00
100+ TRIALS. ONE PATIENT POOL. WHO GETS THERE FIRST?	11:15	16:00
	12:00	18:00
WHY FEASIBILITY OFTEN LIES		
GLOBAL RECRUITMENT STRATEGIES THAT DELIVER REAL PATIENTS		
HOW TO CHOOSE SITES THAT OUTPERFORM COMPETITORS		

FIRST PATIENT IN: 30 DAYS AFTER SUBMISSION. YES, IT IS POSSIBLE

THE STRATEGIC ROLE OF GEOGRAPHY IN REGULATORY SPEED AND PATIENT ACCESS

CHINESE BIOTECH VALUE CREATION: THE INVESTOR'S PERSPECTIVE

OPPORTUNITIES FROM SEED TO GROWTH CAPITAL

THE ROLE OF GLOBAL CLINICAL DATA IN INCREASING ASSET CREDIBILITY AND VALUATION

CLINICAL TRIALS IN THE AGE OF AI: BREAKTHROUGH OR BUZZWORD?

AI PROMISES FASTER TRIALS, SMARTER DESIGN, AND BETTER PATIENT RECRUITMENT, BUT WHEN WILL ITS TRUE IMPACT MATERIALIZE?

GENERAL Q&A

REVIEW OF THE DAY